Drug
Regn5381
Regn5381: highest development phase Phase 2, developed by Regeneron. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Regeneron
Trials
| Drug | Phase | Indication |
|---|---|---|
| REGN5381 NCT05353166 | Phase 2 | Heart Failure |
| REGN5381 NCT06833190 | Phase 2 | Uncontrolled Hypertension |
Latest
No recent events.
Follow Regn5381 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.